BioTuesdays

Tag - Paul Matteis

Eliem-Therapeutics

Stifel starts Eliem Therapeutics at buy; PT $35

Stifel launched coverage of Eliem Therapeutics (NASDAQ:ELYM) with a “buy” rating and price target of $35. The stock closed at $27.56 on Sept. 3. Eliem is a clinical-stage biotechnology company focused on developing...

Acumen

Stifel starts Acumen Pharma at buy; PT $27

Stifel launched coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $27 price target. The stock closed at $17.08 on July 23. Acumen is a biotechnology company focused on the development of a next...

Xenon Pharma

Stifel ups Xenon Pharma PT to $31 from $23

Stifel raised its price target for Xenon Pharmaceuticals (NASDAQ:XENE) to $31 from $23, ahead of Phase 2b focal seizure data expected in the third quarter this year. The stock closed at $17.97 on April 23. “From our...

Stifel cuts Acorda Therapeutics PT to $1 from $2.50

Stifel reduced its price target for Acorda Therapeutics (NASDAQ:ACOR) to $1 from $2.50 and maintained its “hold” rating, citing lower than expected first quarter revenue for its Inbrija inhaled formulation of levodopa...